The authors describe a novel method for the quantitation of differential levels of biomolecules using unlabeled samples and protein-binding arrays for assessing differential expression. Traditional affinity arrays, whether in microplates or protein microarrays, suffer from a few common problems-a shortage of characterized antibodies and highly variable affinities for those available. Also, the assayed proteins could be present in a wide range of concentrations and physicochemical properties, so that it becomes an onerous task to optimize assay conditions for each antibody-antigen pair. Currently, this restricts parallel affinity assays to a low number of carefully selected antibodies and restricts the development of highly multiplexed parallel affinity assays. A displacement strategy allows the use of a much wider range of antibodies, reducing the requirement for matched affinities. The competitive assays described here also show a much higher tolerance for nonspecific background noise. The range of assayed protein concentrations is only limited by the sensitivity of the detection system used. (Journal of Biomolecular Screening 2003:257-263) 
INTRODUCTION
C HARACTERIZATION OF THE COMPLEMENT of expressed proteins from a single genome is a central focus of the evolving field of proteomics. Because one genome produces many proteomes and the number of expressed genes in a cell can exceed 10,000, the characterization of thousands of proteins to evaluate proteomes requires a high-throughput, automated process. Currently, differential proteomics is performed using 2-D gels 1 or random affinity matrices, 2 which display a limited number of proteins requiring downstream identification. Methods of detecting protein expression profiles have important applications in, for example, tissue typing, forensic identification, toxicology testing, and clinical diagnosis. Microarray formats for the quantitative detection of proteins (including antibody and antigen capture) have been developed for diagnosis 3 and protein-protein interaction discovery. 4 Activities of many proteins can be grossly affected by posttranslational modifications such as phosphorylation and glycosylation. A nucleic acid array cannot detect such effects. A highthroughput system for quantitative direct detection of proteins such as a microarray format is desirable in proteomics applications for diagnosis, pharmacoproteomics, identification of markers of disease, and drug target discovery.
Current array-based proteomics techniques are in their infancy and suffer from a variety of problems, including the isolation of sufficient numbers of high-affinity ligands cognate for the proteins of interest. [5] [6] [7] In addition, there are nonspecific binding and background issues whereby the process of labeling proteins can obscure specific binding. There are also sample labeling issues whereby the inherent heterogeneity of proteins, polypeptides, and peptides means that they all take up label to different extents, making absolute quantitation of expression levels complex. 8 Inherent in labeling a sample is the need to purify the sample from the unbound reactive label. Because of sample losses during purification, larger amounts of starting sample are required, although there have been developments in this area in cDNA microarray applications. 9 Another principal difficulty highlighting the difference between protein-antibody interactions and nucleic acid complementary chain interactions is that protein or antibody labeling methods use reactive amino acid side chains to attach the label. Labeling of such reactive side chains can interfere with binding to affinity reagents.
Another major difference between nucleic acid arrays and protein arrays is that for any arrayed nucleic acid, the affinity of its interaction with a corresponding complementary strand is a product of length up to a plateau value. The affinity of interaction is thus similar for all nucleic acid fragments of similar length. However, antibody-antigen pairs show a wide range of affinities irrespective of size. In the context of an antibody array, these differences in affinities can result in a wide range of signal intensities even if equimolar amounts of a labeled sample are added to an array of cognate antibodies. Moreover, highly abundant proteins may fully saturate the immobilized antibody and mask any differential binding signal between two samples. The latter problems taken together mean that any apparent differences in the direct binding signals obtained between 2 different samples (e.g., diseased vs. normal tissue) should not be used to indicate the absolute abundances of the proteins in the 2 samples; the relationship between the binding signal strength and the protein concentration requires calibration. The problem is exacerbated if the aim is to compare differential expression between different cell or tissue types, whereby the generation of calibration curves for each protein would be a daunting task. Arraying different amounts of antibodies in inverse proportions to the affinity of a given antibody is also fairly impractical.
The competitive strategy described here is applicable to arrayed antibodies, capture agents, or other interacting biomolecules and permits the assessment of differential expression of analytes. The method allows a high degree of multiplexing, is tolerant toward high levels of nonspecific binding, and does not require any potentially interaction-disrupting labeling of the experimental samples. Most particularly, it enables the comparison of unlabeled experimental and reference samples over a wide concentration range.
MATERIALS AND METHODS

Chip preparation and protein binding
Hydrogel glass slides (Packard Bioscience, Meriden, CT) were soaked overnight in 50% glutaraldehyde, washed with H 2 O, and air-dried. Antibodies were dispensed onto acrylamide-based pads using a BioChip Arrayer with Piezo-electric tips (Packard Bioscience, Meriden, CT). A total of 72 antibodies were arrayed in quadruplicate onto each slide. Slides were incubated overnight in a humidified chamber prior to washing by Tris-buffered saline (0.05 M Tris, 0.15 M NaCl, pH 7.6), glycine (1.5% w/v in water), and bovine serum albumin (1% w/v final) at room temperature (RT) for 2 h, followed by a final rinse in water before drying. Protein extracts of ovary and kidney were obtained from Clontech. Ovary sample was labeled with iodoacetamide-cy5 (Oxford GlycoSciences, UK) and purified by gel filtration columns. The equivalent of 1 µg of the labeled ovary sample was used for each individual hybridization. Competitive unlabeled proteins (ovary or kidney) were added as either 1 µg of protein (near IC 50 displacement) or 10 µg of protein (near 90% displacement). Slides were hybridized for 1 h at RT followed by three 2-min washes with H 2 O.
Data acquisition and analysis
The incorporation of fluorescent dye molecules into immobilized antibodies and acrylamide gel was measured using a BioChip Imager Confocal laser-scanning system (Packard BioScience, Meriden, CT). The slides were scanned at the highest resolution of 10 µm. Total fluorescence signals corresponding to each spot (ob-tained by hybridization in the presence of various displacing samples) were recorded. Mean values (obtained by averaging the quadruplicate readings for each antibody) were used for analysis. A set of values corresponding to hybridization in the presence of unlabeled kidney sample ("a kidney") was subtracted from an analogous set obtained when unlabeled ovary was used ("an ovary"). If the subtraction results in a positive value, this indicates that the signal measured for "ovary" is stronger (i.e., unlabeled kidney produces a stronger displacement, meaning a higher concentration of the corresponding protein in the kidney sample). A negative value means lower protein expression in the kidney sample. To compensate for differences in displacement values due to different amounts of protein used for the displacement of individual samples, which resulted in a strong bias toward one or another sample, a complete set of subtracted values was averaged, and the obtained average value was subtracted from each individual peak. Such normalization is able to compensate for the overall differences in the amount of displacing reagents if they are within 2 log units of concentrations of their respective IC 50 .
RESULTS AND DISCUSSION
Binding displacement assay
In a traditional affinity assay, in which labeled antigen or antibody (or secondary reagent in sandwich assays) is added to immobilized antibody (or antigen, respectively), the detected signal is proportional to the amount of antigen. In a displacement (or competition) strategy, at least 3 components are used (e.g., immobilized antibody, labeled antigen, and unlabeled antigen). The signal detected will generally be inversely proportional to the concentration of the assayed unlabeled antigen. If individual antigens are being assayed, any of the above approaches can be applied. However, if a multiplexed format is sought (in which more than 1 antigen is assayed in parallel), major differences start to emerge. A schematic diagram in Figure 1A illustrates what might happen if 2 antibodies (anti-A and anti-B), uncharacterized for multiplexed assays, are used in parallel for analysis of the expression of protein targets A and B. First, the measurable concentration ranges (MCRs) for each target are limited from both below (by signal detection threshold [SDT]) and above (due to signal saturation and resolution of the detector system used). The MCRs for each target are also dependent on the affinity of their respective antibodies. Lower concentrations may be detected with higher affinity antibodies, but the binding will saturate at lower target concentrations as well and vice versa. So expression levels of 2 targets (A and B) may not be measured simultaneously if the concentration of each target does not fall into the respective MCR ranges. Moreover, due to the nonlinear (exponential) character of the binding isotherm, which becomes less steep toward saturating concentrations ( Fig. 1A) , measurements at higher target concentrations are subject to increased errors and become limited by the experimental data dispersion as well as the resolution of the detection system. If expression of tar-gets A and B are compared between 2 different samples (such as normal and disease tissues), their differential expression may not be seen (if target concentration is out of their MCRs), and even if it is, the difference detected may not be quantified. One way to quantify or validate measurements would be to calibrate the whole MCR (for each antibody-antigen pair) and to assay at different sample dilutions to suit each individual target, a task that is impractical if applied to an antibody microarray containing more than a few different antibodies. Therefore, highly multiplexed affinity assays require the development of new formats.
On the other hand, if the 2 targets (A and B) are analyzed using a competition assay, when, for example, a set of labeled reference targets (A and B) are bound to respective antibodies in the absence or presence of unlabeled A-and B-containing samples from 2 different sources, the differences can be quantitatively estimated. Displacement of binding by competition results in a sigmoidal curve spanning more than 6 orders of magnitude of ligand concentration before reaching a plateau at very low and very high displacer concentrations (no displacement or complete displacement, respectively):
In the above equation (also known as a 3-parameter logistic equation), the "MAX signal" is the signal detected without a displacing compound present, and "Background" is the signal detected in the presence of an excess of unlabeled compound present.
This displacement strategy is advantageous for a number of reasons. First, this strategy allows identification of nonspecific binding, thus making the strategy tolerant to high background levels, a not-uncommon feature of protein microarrays. Second, in a displacement experiment, results do not depend on the number of binding sites on the surface (i.e., immobilized antibodies), unlike in saturation binding, in which the shape of a binding isotherm depends on the B max (a number of immobilized binding sites, e.g., antibodies) as well as on the antibody affinity. Most important, however, the shape of a typical sigmoidal displacement curve is relatively steep over 4 orders of magnitude of a displacer concentration, and the above equation assumes a standard slope (which approximates to 1, using a logarithmic scale for displacer concentrations), whereby the response goes from 10% to 90% of the "(MAX signal -Background)" as the displacer concentration increases over about 2 log units. Therefore, errors of measurement may be minimized for virtually any target concentration (any displacer), provided that the concentration of fluorescently (or otherwise) labeled reference differs little from the concentration of the target to be assayed (i.e., when displacer concentration is within ± 1 log unit of respective IC 50 ). A displacement strategy therefore allows, at least in principle, the running of highly multiplex parallel affinity assays, as long as the concentration of each labeled reference antigen is adjusted such that it is at least of the same order of magnitude as the assayed targets. Although such a requirement might be limiting in practice, displacement has many advantages over a traditional saturation-binding assay if applied to affinity arrays.
Self-displacing probes
Below we describe one particular experimental layout, which circumvents the main practical limitation of the displacement strategy described above-the need to adjust the labeled reference concentration for each assayed target to decrease experimental errors (as described above). We found that the most convenient way to achieve this is to displace binding of the labeled sample with the same but unlabeled sample. In a case when a single target is analyzed, this would be equivalent to building a standard displacement (competition) curve. However, for highly multiplexed samples (e.g., cellular lysates), displacing the binding of such a sample to, for example, an array of antibodies with an equal amount of the same but unlabeled sample will result in near-identical, approxi- mately 50% signal displacement for each individual antibodyantigen pair. If the amount of unlabeled sample used is 10-fold greater than the amount of labeled sample, the decrease in the bound signal will be approximately 10-fold and so on. To achieve exactly 50% (or 90%, etc.) displacement, the concentration of samples should be well above their K D (see also Fig. 1B) , and this is possible using higher sample concentrations. Figure 2 shows displacement data obtained for an array of 72 antibodies, incubated and bound with a labeled ovary lysate and displaced by either unlabeled ovary lysate or unlabeled kidney lysate. The plots ( Fig.  2A-D) show the differences (ovary displacement minus kidney displacement) obtained at an approximately 90% overall displacement level (e.g., near 10-fold excess of the unlabeled sample, by total protein concentration). Normalized data were obtained as described in Materials and Methods. The profiling data in Figure 2 are qualitative but could be made fully quantitative if additional arrays are used for the reference sample to define the signal range and the background (e.g., 1 array for total binding, 1 for~IC 50 displace-ment, and 1 for complete displacement). In all cases, at least 1 array is required for each experimental sample. Importantly, regardless of the format (qualitative or fully quantitative analysis), the displacement protocols described herein result in reliable and meaningful data, unlike a direct hybridization approach, which works best with nucleic acids. The results (Fig. 2) indicate a number of differentially expressed proteins. The highest differential expression was detected in the anti-HLA-class I antigen antibody ( Fig. 2A, peak 4) , antiblood-brain barrier (neurothelin) HT-7 antibody ( Fig. 2A, peak 6 ), anti-MAD (helix loop helix-leucine/zipper transcription factor) antibody ( Fig. 2A, peak 14) , anti-phosphothreonine antibody ( Fig.  2C, peak 6 ), anti-IkB alpha antibody ( Fig. 2C, peak 13) , and anti-TATA-binding protein antibody ( Fig. 2C, peak 15 ). Our results are in a good agreement with data reported previously. For example, reports by Le et al. 10 and Dolo et al. 11 indicate the expression of HLA-1 in the ovary reaching especially high levels in ovarian tumors. The negative value of the bars in Figure 2A tive of higher HLA-1 content in the ovary sample we tested. The blood-brain barrier protein recognized by the HT-7 antibody is predominantly expressed by brain endothelial cells. It has also been reported to be expressed in basolateral membranes of kidney tubules, 12 which is in a good agreement with our results: we found a higher level of this protein in kidney lysate compared to ovary (Fig.  2, panel A, no. 6 ). Anti-phosphothreonine antibody signal (Fig.  2C, no. 6 ) is indicative of a higher level of phosphorylated proteins in kidney, but we have no independent confirmation for these data. MAD protein genes are present in both ovary and kidney according to UniGene collection, 13 but no other MAD expression data (on either mRNA or protein level) were available for us. The expression profile of IkB alpha protein ( Fig. 2C, peak 13 ) correlates with the expressed sequence tag (EST) distribution for the mRNA version of IkB alpha, which shows an approximately 2-fold excess of IkB alpha ESTs in kidney compared to ovary when all tissues and ESTs are used to create a normalized database of EST representation (http://www.ncbi.nlm.nih.gov/UniGene/). The TATA-binding protein (TBP) is a transcription factor, which plays an important role in eukaryotic gene expression and is present in both ovary and kidney on the mRNA level (UniGene) and also has been previously shown to be expressed as a protein in kidney cells. 14 Our protein profiling data (Fig. 2) are therefore in a good overall agreement with expression data generated by other independent means. The competitive approach described is especially useful when 2 or more experimental protein samples are being compared (e.g., for routine diagnostic applications). Presume an immobilized antibody is incubated with a saturating concentration of its antigen, a situation easily achievable in practice, and labeling of the antigen does not affect the affinity of interaction. If an equal amount of the same but unlabeled antigen is added, both labeled and unlabeled antigen molecules will compete equally for the available antibody binding sites, and thus the amount of labeled antigen bound will reduce 2-fold. If labeling changes the affinity of interaction (i.e., reduces or increases it), then lower or higher concentrations of the unlabeled antigen would be required to achieve an equivalent 50% displacement. The IC 50 for the unlabeled antigen would become respectively lower or higher. If 2 or more different samples are being compared in parallel in this format using, for example, multiple normal and/or disease samples, it will be the same unlabeled antigen molecules competing with the same labeled reference samples in each case. Because all experimental samples have the same unlabeled antigen molecules (i.e., identical, unlabeled, unmodified, etc.), their respective IC 50 s for displacing the labeled reference will be identical. Such a competitive binding will only yield equal displacement values when equal amounts of the antigen are present in each sample. This remains true regardless of the reference sample concentration or the antibody affinity. For example, if unlabeled antigens are present at equal concentrations at approximately IC 50 in the 2 experimental samples, the displacement achieved in both cases will be identical (i.e., approximately 50% of the maximum specific binding). If unlabeled antigens are present at equal concentrations but at a ×10-fold excess relative to the IC 50 , the displacement achieved in both cases will nevertheless be identical (i.e., approximately 90% of the maximum specific binding). Moreover, the "Background" and "MAX binding" values (see formula above) will be identical in all experiments run in parallel because "MAX binding" is measured without adding any unlabeled competitors, and the "Background" is the signal measured under total displacement conditions and will not affect the results. In practice, the "Background" is ideally kept to a minimum to reduce experimental errors.
MEANS
Displacement using different concentrations of unlabeled samples
To test whether our protocol is tolerant to variability in the protein concentration of the samples (which could be the case because of handling errors or if a protein concentration is unknown for an experimental sample), we displaced the binding of labeled sample with different amounts of unlabeled samples. Labeled ovary lysate (as used for the experiment described earlier) was displaced with an equivalent amount of the unlabeled reference (ovary), but unlabeled experimental (kidney) sample was applied in ×10 excess. Results are shown in Figure 3A -D. Normalization of the data (to avoid bias toward sample used in excess) was as described in Materials and Methods. Data from Figures 2 and 3 clearly result in similar expression profiles, which proves that the presented displacement protocol is tolerant to variability in the amount of unlabeled samples used. We also compared ×10-fold excess ovary to ×1-fold kidney (data not shown), which also resulted in a profile similar to the one shown in Figure 2 .
CONCLUSIONS
We have previously shown that using a traditional saturation binding assay is possible in a microarray format, and differential expression of proteins can be seen as a more scattered plot (tissue 1 vs. tissue 2 extracts) with low correlation coefficient R~0.6, unlike R~0.9 for identical tissues. 15 However, such saturation analysis cannot reveal differential expression of 2 targets expressed, for example, at saturating concentrations or between 2 weak differential signals masked by a strong constant background. The selfdisplacement protocols described here allow highly multiplexed affinity assays because the results obtained no longer depend so much on the affinities of the reagents used or concentrations of individual proteins in the samples tested.
The antibody affinities will remain a limiting factor in determining the sensitivity of both traditional analysis (i.e., saturation binding) and the approach described in this paper. There exists a number of signal amplification techniques, compatible with protein arrays. These include more traditional ELISA (enzyme-linked immunosorbent assay) or ECL (enhanced chemiluminescence)based approaches, a Rolling Circle Amplification (RCAT), capable of microchip format applications and up to 4 orders of magni-Assay Formats for High-Throughput Affinity Arrays tude signal amplification 16 , or the use of protein-DNA fusions [17] [18] , where proteins can be labelled to a much higher degree through the associated DNAs thus enabling detection of protein molecules present in low abundance on an array. To maintain quantitative character of an assay, a more efficient protein labelling (i.e., through protein fusions, etc.) is preferred over signal amplification approaches (i.e., ELISA, ECL, or especially RCAT), which also take a longer time to complete.
Another modification of a displacement technique would be to use a generic proteome (protein mixtures) for use with any affinity assay. Such generic samples could, for example, be obtained by mixing a few different protein preparations, cell lysates, and so forth. A major advantage of such a procedure would be in having only 1 (experimental) sample to be assayed and characterized, whereas a generic "reference" could be used for any experiment. This would further simplify running "protein arrays." One disadvantage may be that potentially imperfect competition conditions could occur for some of the assayed proteins, resulting in a more qualitative assay. This might, however, be a preferred option for some routine applications.
The approaches described here have a number of significant advantages over the current direct binding approaches. Most important, the method described can result in a fully quantitative analysis of differential protein expression. Also, the antibodies used do not require extensive characterization, and the amount of spotted (immobilized) antibody is not so important, as the displacement equation is largely independent on these values. Another important factor is that the experimental sample does not require labeling, resulting in no protein damage or losses, shorter processing times, and cheaper experiments. As a consequence, the amount of sample required can be lower. Using the described method allows the comparison of unlabeled samples, thus avoiding variability due to sample modifications. Also, wide ranges of protein concentration can be assayed. The described method is highly tolerant of background binding; this may be further improved by using a wider range of displacing reference sample concentrations. 3 . Protein expression profiling using displacement strategy. An array of 4 × 18 (72 in total) antibodies was hybridized to labeled ovary lysate in the presence of unlabeled ovary lysate or unlabeled kidney lysate (similar to the experiment described in Fig. 2 ). Kidney lysate was used in ×10 excess compared to the labeled reference sample, whereas an unlabeled ovary lysate was used at a 1:1 ratio (by total protein). Bars represent difference between ovary sample minus kidney sample (see Materials and Methods for detailed description). Each panel corresponds to a single row of antibodies. Left bar in each case shows mean values obtained by averaging data from 4 antibody spots (each antibody was printed in quadruplicate). Right darker bar in each case shows that data were obtained by averaging 2 antibody spots (2 outlying values were disregarded). The 6 most differentially expressed signals correspond to the same antibodies as described in the Figure 2 legend, which confirms high tolerance of the reported method to variability in protein concentrations.
